Antibiotics used none/G/P-S/A G G G none none P-S none P-S P-S C C C C none Dosing scheme   single  single  single  single  single  single  single  single  single  sesingle  single  single  single 5-26 12-18 4 24 4 Platforms: AXN=Maestro (Axion Biosystems), CLY=CellOPTIQ (Clyde Biosciences), ECR= CardioECR (ACEA Biosciences), AMD= AlphaMED64 (Alpha MED Scientific), MCS= MEA2100 (Multichannel Systems) Antibiotics used in hiPSC-CM maintenance medium (not in the recording medium): G= gentamicin, P-S= penicillin/streptomycin, A= amphotericin B, C= ciprofloxacin. Dosing scheme: single (one drug concentration per well) or seq =sequential (increasing drug concentration in the same well) Recording media CDI iCell 2 maintenance medium (Cellular Dynamics), AXG=Cor.4U maintenance medium (Ncardia), SF1= DMEM (Gibco #11966-025) + 10mM galactose + 1mM sodium pyruvate, SF2=Serum-free Cor.4U medium (Ncardia). Plating areas (in mm 2 ) were as following depending on a platform, AXN: 5 for iCell 2 , 7 for Cor.4U; ECR: 19.6; CLY:32; AMD: 7.8; MCS: 0.45. 
Supplemental
L 0 * -one site noticed cloudiness after drug addition to the cells (no adjustments were done to the dilution protocol) 

Model 1:
Using Formula (1) and Supplemental Table 5 estimates for the predictors we find for P1: 1 1 4 7 0.1311 0.00687 74 0.0232 0.34 0 0.3852 → 1 0.595 i.e. predicted probability of the compound to have high or intermediate TdP risk is 59.5% and probability to have a low TdP risk is 40.5%.
Model 2:
Using Formula (2) and Supplemental Table 5 estimates for the predictors we find for P2a (probability of high versus low TdP risk): 2 1 4 7 2.1102 0.2211 0 0.00105 74 0.0338 0.34 0 2.021 → 2 0.117 i.e. predicted probability of the compound to have high TdP risk is 11.7%. Using Formula (3) and Supplemental Table 5 estimates for the predictors we find for P2b (probability of intermediate versus low 
